From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.

"Declarations Ethics approval and consent to participateSamples derived from Schwannian-stroma poor, poorly differentiated, NB primary tumors at relapse and BM-infiltrating NB cells from patients at either onset or relapse were provided by BIT (Integrated Tumor Bio-Bank of Gaslini Institute, Tissue Section), Istituto G. Gaslini, Genoa, Italy. All procedures were performed in accordance with relevant guidelines and regulations and approved by the CER (Regional Committee), first under the protocol ANTECER_Neuroblastoma: 15/12/2016, amendment 065_16/09/2019, and subsequently under the protocol EudraCT: 2022-000558-27. Informed consent was obtained from each patient in accordance with the Declaration of Helsinki. Male NOD/SCID/IL2Rgammanull (NSG) mice (Charles River Laboratories, Milan, Italy) were housed under pathogen-free conditions. In accordance with the 3Rs policy, experiments were reviewed and approved by the licensing and ethical committee of Ospedale Policlinico San Martino and by the Italian Ministry of Health (n. 661/2016-PR and 883/2020-PR). Informed consentSupporting data and materials are available. Consent for publicationAll authors approved the final version of the manuscript. MP had responsibility for the decision to submit for publication. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding The study was supported by the Italian Ministry of Health (“Ricerca Finalizzata 5 per mille” to M.P.) and partially supported by (i) Fondazione Italiana per la Lotta al Neuroblastoma (M.P. and M.C); (ii) Associazione Oncologia Pediatrica e Neuroblastoma (OPEN) (M.C. and M.P.); (iii) Associazione Italiana per la Ricerca sul Cancro (Investigator Grant n. 24397 to F.P. and n. 25796 to M.C.); (iv) Italian Ministry of Health (“Ricerca Corrente” to M.P.). V.B. is a recipient of AIRC ID.24397 contract."